Close popup
CRESTOR® (rosuvastatin calcium)



 

References

  • AstraZeneca Pharmaceuticals LP. AstraZeneca competitive price sheet: prices as reported by First Databank as of 9/10/08 [Excel spreadsheet compiled by Janet Rosenberg].
  • AstraZeneca Pharmaceuticals LP. Rosuvastatin drug safety—postmarketing experience: spontaneous adverse event reporting information. www.rosuvastatininformation.com. Accessed July 2008.
  • AstraZeneca Pharmaceuticals LP. Rosuvastatin Information Web site. www.rosuvastatininformation.com. Accessed July 23, 2008.
  • Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006;151(5):975.e1-975.e9.
  • Bays HE, Deedwania PC, Jones PH, Caplan RJ, Blasetto JW. Comparative effects of statins on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in patients ≥65 years of age. Poster presented at Annual Scientific Meeting of the American Geriatrics Society. Las Vegas, NV, May 17-21, 2004.
  • Berne C, Siewert-Delle A; URANUS Study Investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;4:7.
  • Betteridge DJ, Gibson JM; ANDROMEDA Study Investigators. Effects of rosuvastatin on lipids, lipoproteins, and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med. 2007;24(5):541-549.
  • Crouse JR III, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
  • Data on File, 265803, AstraZeneca Pharmaceuticals LP.
  • Data on File, 266987, AstraZeneca Parmaceuticals LP.
  • Data on File, 266992, AstraZeneca Pharmaceuticals LP.
  • Data on File, 267038, AstraZeneca Pharmaceuticals LP.
  • Data on File, 267725, AstraZeneca Pharmaceuticals LP.
  • Data on File, 267733, AstraZeneca Pharmaceuticals LP.
  • Data on File, 268255, AstraZeneca Pharmaceuticals LP.
  • Data on File, 278682, AstraZeneca Pharmaceuticals LP.
  • Data on File, 288160, AstraZeneca Pharmaceuticals LP.
  • Data on File, 288158, AstraZeneca Pharmaceuticals LP.
  • Faergeman O, Hill L, Windler E, et al; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-228.
  • Ferdinand KC, Clark LT, Watson KE, et al; ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006;97(2):229-235.
  • Fingertip Formulary®. Percentage of covered lives without prior approval. Glen Rock, NJ: Fingertip Formulary LLC. www.fingertipformulary.com. Accessed June 1, 2009.
  • García-Rodríguez LA, González-Pérez A, Stang MR, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf. 2008;17(10):953-961.
  • García-Rodríguez LA, Massó- González EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf. 2008;17(10):943-952.
  • Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO Study. Pharmacoepidemiol Drug Saf. 2006;15(7):435-443.
  • Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
  • Johansson S, Ming EE, Wallander MA, et al. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf. 2006;15(7):454-461.
  • Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;93(2):152-160.
  • Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin. 2005;21(11):1865-1874.
  • Libby P. The vascular biology of atherosclerosis. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:921-937.
  • Lloret R, Ycas J, Stein M, Haffner S; STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. 2006;98(6):768-773.
  • McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf. 2006;15(7):444-453.
  • McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-698.
  • National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Bethesda, MD: National Institutes of Health; 2002. NIH Publication No. 02-5215.
  • National Institutes of Health, National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Cholesterol with TLC. Bethesda, MD: National Institutes of Health; December 2005. NIH Publication No. 06-5235.
  • New Drug Application for Lipitor (4-month safety update). Parke-Davis Pharmaceutical Research; December 17, 1996.
  • New Drug Application for Pravachol (medical officer’s review and evaluation of NDA report). E.R. Squibb & Sons Ltd.; October 31, 1991.
  • New Drug Application for Zocor (simvastatin safety update II). Merck Sharp & Dohme Research Laboratories; December 23, 1991.
  • Prescribing Information for CRESTOR. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
  • Prescribing Information for Lescol. Novartis, East Hanover, NJ.
  • Prescribing Information for Lipitor. Pfizer US Pharmaceuticals, New York, NY.
  • Prescribing Information for Mevacor. Merck & Co., Inc., Whitehouse Station, NJ.
  • Prescribing Information for Pravachol. Bristol-Myers Squibb Company, Princeton, NJ.
  • Prescribing Information for Vytorin. Merck/Schering-Plough Pharmaceuticals, North Wales, PA.
  • Prescribing Information for Zocor. Merck & Co., Inc., Whitehouse Station, NJ.
  • Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I) study. Am Heart J. 2004;147(4):705-712.
  • Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882-888.
  • Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology. 2007;107(4):433-443.
  • Sorof J, Berne C, Siewert-Delle A, Jørgensen L, Sager P; URANUS Study Investigators. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;72(1):81-87.
  • Vidt DG, Harris S, McTaggart F, Dtmarsch M, Sager PR, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006;97:1602-1606.
  • Wolffenbuttel BH, Franken AA, Vincent HH; Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes — CORALL Study. J Intern Med. 2005;257(6):531-539.